ClinicalTrials.gg
CompletedNCT04225871RAISE-XTUpdated Oct 16, 2026

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

A Phase 3 interventional study of zilucoplan (RA101495) in Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL. Completed at 70 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Myasthenia Gravis by UCB S.A. — 5 open to participants now, 7 under way, 5 of them phase 3. Myasthenia Gravis · UCB S.A..

Enrollment
Largest of 18
200 · median 45
Started
2019
with 3 others
Phase 3
12 of 18
3 open now
Registered
4th of 18
by date

Among the 18 studies in Myasthenia Gravis by UCB S.A., this one has the largest enrollment, is one of 4 that started in 2019, is one of 12 in phase 3, and was the 4th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

5 of the 18 studies in Myasthenia Gravis by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Myasthenia Gravis by UCB S.A., or all of them as a file.
02

Study summary

The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of a qualifying zilucoplan study

Exclusion criteria

Exclusion Criteria:

  • With the exception of a prior zilucoplan trial, participation in another concurrent clinical trial involving an experimental therapeutic intervention (participation in observational studies and/or registry studies is permitted)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    0.3 mg/kg zilucoplan (RA101495)

    Drug: zilucoplan (RA101495)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    A treatment-emergent adverse event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.

    Time frame: From Baseline (Day 1) to Safety Follow-Up Visit (up to 36 months)

Secondary outcomes

  1. Change from Baseline to Week 12 in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score

    The MG-ADL profile provides an assessment of MG symptom severity and measures 8 items on a 0-3 scale, with 0 being the least severe. The total sum of the 8 items represents the ADL score. The ADL score can range from 0 (least severe) to 24 (most severe).

    Time frame: From Baseline (Day 1) to Week 12

  2. Change from Baseline to Week 12 in the the Quantitative Myasthenia Gravis (QMG) Score

    The QMG test is a standardized quantitative strength scoring system and measures 13 items on a 0-3 scale, with 0 being the least severe. The total sum of the 13 items represents the QMG score. The QMG score can range from 0 (least severe) to 39 (most severe).

    Time frame: From Baseline (Day 1) to Week 12

  3. Change from Baseline to Week 12 in the Myasthenia Gravis Composite (MGC) Score

    The MGC is a 10-item scale that has been used to measure the clinical status of patients with Myasthenia Gravis (MG) in order to evaluate treatment response. The MGC has 4-point Likerttype Scale response options ranging from 0 to 2, 3, 4, 5, 6 or 9 according to the item (weighted response options). The total score is the sum of all items (range 0-50) where higher scores indicate more severe impairment due to the disease.

    Time frame: From Baseline (Day 1) to Week 12

  4. Change from Baseline to Week 12 in the Myasthenia Gravis - Quality of Life revised (MG-QOL15r) Score

    The MG-QOL15r is a 15-item survey that was designed to assess quality of life in patients with MG. The MG-QoL has 3-point Likert Scale response options ranging from 0 to 2. The MGQoL15r score can range from 0 to 30, where higher scores indicate more severe impact of the disease on aspects of the patient's life.

    Time frame: From Baseline (Day 1) to Week 12

07

Study locations

70 sites
  • Mg0011 41
    Mobile, Alabama 36604, United States
  • Mg0011 116
    Phoenix, Arizona 85028, United States
  • Mg0011 31
    Irvine, California 92697, United States
  • MG0011 4
    Los Angeles, California 90033, United States
  • Mg0011 220
    Pasadena, California 91101, United States
  • Mg0011 160
    San Francisco, California 94115, United States
  • Mg0011 24
    New Haven, Connecticut 06511, United States
  • Mg0011 27
    Washington D.C., District of Columbia 20052, United States
  • Mg0011 25
    Tampa, Florida 33612, United States
  • Mg0011 135
    Augusta, Georgia 30912, United States
  • Mg0011 188
    Glenview, Illinois 60026-1339, United States
  • Mg0011 156
    Indianapolis, Indiana 46202, United States
  • Mg0011 32
    Kansas City, Kansas 66160, United States
  • Mg0011 33
    Detroit, Michigan 48201, United States
  • Mg0011 49
    East Lansing, Michigan 48824, United States
  • Mg0011 134
    Columbia, Missouri 65201, United States
  • Mg0011 117
    Las Vegas, Nevada 89145, United States
  • Mg0011 30
    Buffalo, New York 14202-1102, United States
  • Mg0011 123
    Great Neck, New York 11021, United States
  • Mg0011 23
    New York, New York 10021, United States
  • Mg0011 47
    New York, New York 10029, United States
  • Mg0011 22
    Chapel Hill, North Carolina 27599, United States
  • Mg0011 122
    Cleveland, Ohio 44195, United States
  • Mg0011 38
    Columbus, Ohio 43210, United States
  • Mg0011 40
    Pittsburgh, Pennsylvania 15212, United States
  • Mg0011 128
    Charleston, South Carolina 29425-8908, United States
  • Mg0011 28
    Cordova, Tennessee 38018, United States
  • Mg0011 131
    Austin, Texas 78759, United States
  • Mg0011 19
    Dallas, Texas 75390, United States
  • Mg0011 39
    Salt Lake City, Utah 84105, United States
  • Mg0011 164
    Charlottesville, Virginia 22903, United States
  • Mg0011 154
    Seattle, Washington 98195, United States
  • Mg0011 45
    Milwaukee, Wisconsin 53215, United States
  • Mg0011 11
    Montreal, Canada
  • Mg0011 204
    Lille, France
  • Mg0011 118
    Nice, France
  • Mg0011 105
    Paris, France
  • Mg0011 137
    Strasbourg, France
  • Mg0011 150
    Göttingen, Germany
  • Mg0011 129
    Tübingen, Germany
  • Mg0011 132
    Milan, Italy
  • Mg0011 126
    Roma, Italy
  • Mg0011 151
    Chiba, Japan
  • Mg0011 136
    Hanamaki-shi, Japan
  • Mg0011 179
    Kita-gun, Japan
  • Mg0011 153
    Meguro-ku, Japan
  • Mg0011 146
    Nagasaki, Japan
  • Mg0011 169
    Narita, Japan
  • Mg0011 152
    Sapporo, Japan
  • Mg0011 144
    Sendai, Japan
  • Mg0011 163
    Shinjuku-ku, Japan
  • Mg0011 141
    Tokyo, Japan
  • Mg0011 140
    Bergen, Norway
  • Mg0011 143
    Oslo, Norway
  • Mg0011 195
    Katowice, Poland
  • Mg0011 213
    Katowice, Poland
  • Mg0011 192
    Krakow, Poland
  • Mg0011 193
    Krakow, Poland
  • Mg0011 211
    Krakow, Poland
  • Mg0011 214
    Lodz, Poland
  • Mg0011 205
    Lublin, Poland
  • Mg0011 194
    Nowa Sól, Poland
  • Mg0011 209
    Poznan, Poland
  • Mg0011 201
    Warsaw, Poland
  • Mg0011 210
    Zabrze, Poland
  • Mg0011 133
    Barcelona, Spain
  • Mg0011 168
    Barcelona, Spain
  • Mg0011 138
    Bilbao, Spain
  • Mg0011 119
    Oxford, United Kingdom
  • Mg0011 130
    Sheffield, United Kingdom
08

References and documents

Publications

  • Weiss MD, Freimer M, Leite MI, Maniaol A, Utsugisawa K, Bloemers J, Boroojerdi B, Howard E, Savic N, Howard JF Jr. Improvement of fatigue in generalised myasthenia gravis with zilucoplan. J Neurol. 2024 May;271(5):2758-2767. doi: 10.1007/s00415-024-12209-3. Epub 2024 Feb 24. PubMed 38400914 ↗
  • de la Borderie G, Chimits D, Boroojerdi B, Brock M, Duda PW, Grimson F, Mahoney P, Strimenopoulou F, Cutter G, Aban I, Brauner S, Petersson M, Howard JF Jr, Bennett N. Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis. Ther Adv Neurol Disord. 2024 Sep 21;17:17562864241279125. doi: 10.1177/17562864241279125. eCollection 2024. PubMed 39314260 ↗
  • Hewamadduma C, Freimer M, Genge A, Leite MI, Utsugisawa K, Vu T, Boroojerdi B, Grimson F, Savic N, Vanderkelen M, Howard JF Jr; RAISE-XT study team. Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis. J Neurol. 2025 Jun 12;272(7):457. doi: 10.1007/s00415-025-13113-0. PubMed 40504283 ↗
  • Howard JF Jr, Bresch S, Farmakidis C, Freimer M, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Nowak RJ, Sivakumar K, Smilowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Bloemers J, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Vanderkelen M, Leite MI; RAISE-XT Study Team*. Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study. Ther Adv Neurol Disord. 2024 Apr 17;17:17562864241243186. doi: 10.1177/17562864241243186. eCollection 2024. PubMed 38638673 ↗
  • Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Smilowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI; RAISE Study Team. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023 May;22(5):395-406. doi: 10.1016/S1474-4422(23)00080-7. PubMed 37059508 ↗

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jul 2026, 79 months.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 79 months is above that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2019
First posted
Jan 13, 2020
StartActual
Dec 23, 2019
Primary completionActual
Jul 31, 2026
CompletionActual
Jul 31, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04225871
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jan 13, 2020
Start date
Dec 23, 2019
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026
Last update
Oct 16, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilucoplan

Start the discussion